Folkehelseinstituttet
Not a member yet
10872 research outputs found
Sort by
A qualitative study of the IPS employment specialist role in the context of Nav employment in Norway
No full textpublishedVersio
The outpatient experience questionnaire for child and adolescent mental health services: reliability and validity following a nationwide survey
No full textpublishedVersio
Road traffic noise and incident ischemic heart disease, myocardial infarction, and stroke: A systematic review and meta-analysis
No full textpublishedVersio
Patients' experiences with the treatment of long-term fatigue of unclear cause: a qualitative evidence synthesis
No full textVi har oppsummert kvalitativ forskning om pasienters erfaringer med behandlingstiltak for langvarig utmattelse av uklar årsak, inkludert diagnosene CFS/ME, fibromyalgi, senfølger etter covid-19 og annen langvarig utmattelse. Tiltakene omfattet psykologiske, lærings- og mestrings- og aktivitetsbaserte tiltak. Hovedfunnene på tvers av tiltak viser at: • Mange verdsatte en helhetlig tilnærming som inkluderte både fysiske og psykiske aspekter ved tilstanden, og ønsket anerkjennelse av langvarig utmattelse som en reell kronisk sykdom. • Familieinvolvering ga trygghet og støtte, og mange ønsket at pårørende skulle få mer informasjon. • For mange bidro gruppebehandlinger til støtte og forståelse fra andre, men store grupper kunne gjøre det vanskeligere å dele erfaringer. • Tilpasset og realistisk informasjon økte pasientenes innsikt og mestring. • Konkrete verktøy og mestringsstrategier ble ansett som nyttige. • Symptomer, tidsbegrensninger og livsforhold gjorde det utfordrende å anvende nye ferdigheter i hverdagen. • Terapeutens kunnskap, empati og relasjonelle ferdigheter var avgjørende for en positiv opplevelse. • Kombinasjon av flere behandlingsmetoder ble både verdsatt, men kunne også opplevesutfordrende. Det er begrenset forskning på de enkelte tiltakene og pasientpoulasjonene. Det er et stort behov for videre forskning som utforsker hvordan tiltak kan tilpasses ulike gruppers behov.publishedVersio
Temporal and cross-sectional associations of serum per- and polyfluoroalkyl substances (PFAS) and lipids from 1986 to 2016 − The Tromsø study
No full textIntroduction Per- and polyfluoroalkyl substances (PFAS) have been linked to effects on human lipid profiles, with several epidemiological studies reporting associations between specific PFAS and blood lipid concentrations. However, these associations have been inconsistent, and most studies have focused on cross-sectional analyses with limited repeated measurements. Objective In this study, we investigated associations between serum PFAS concentrations and major blood lipid classes over a 30-year period (1986–2016) and up to five time points. Lipids analyzed included total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG). Methods This study included 145 participants from The Tromsø Study, Norway, who donated plasma samples three to five times over the study period. Linear mixed-effects (LME) models assessed longitudinal associations between PFAS and lipid classes, while multiple linear regression (MLR) models were used for cross-sectional associations. Results LME models demonstrated positive longitudinal associations between perfluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA), perfluorodecanoic acid (PFDA), perfluoroundecanoic acid (PFUnDA), perfluorododecanoic acid (PFDoDA), and perfluorotridecanoic acid (PFTrDA) with TC. Additionally, PFOA, PFDA, PFUnDA, PFDoDA, and PFTrDA were associated with LDL-C, and PFUnDA and summed perfluorooctane sulfonate isomers (∑PFOS) with HDL-C. Cross-sectional analyses corroborated positive associations between the six PFAS compounds and TC at least three times, but the LDL-C and HDL-C associations were not confirmed. Summed perfluorooctane sulfonamide isomers (∑PFOSA) showed a negative association with LDL-C longitudinally, but this was not confirmed cross-sectionally. No associations were observed between PFAS and TG, longitudinally or cross-sectionally. Conclusion Concentrations of multiple PFAS were positively associated with blood lipids in longitudinal analyses, with the most consistent associations observed between six PFCA compounds and TC. These findings highlight the need for further investigation into these complex associations.Temporal and cross-sectional associations of serum per- and polyfluoroalkyl substances (PFAS) and lipids from 1986 to 2016 − The Tromsø studypublishedVersio
Inequalities in somatic comorbidities among immigrants and Norwegians with and without common mental disorders: a national register study
No full textpublishedVersio
Epidemiology and excess mortality of antimicrobial resistance in bacteraemias among cancer patients: A cohort study using routinely collected health data from regional hospital trusts in Oxford and Oslo, 2008-2018
Get PDFpublishedVersio
Utilization of mental health care among people bereaved by suicide in Norway: A trajectory analysis
Get PDFpublishedVersio
Assessment of genetically modified maize DAS1131 for food and feed uses, import and processing under Regulation (EC) No 1829/2003 (application GMFF-2021-1530)
Get PDFThe Norwegian Scientific Committee for Food and Environment (VKM) has assessed an application for approval of the genetically modified maize DAS1131 for food and feed uses, import and processing in the EU. In accordance with an assignment specified by the Norwegian Food Safety Authority (NFSA) and the Norwegian Environment Agency (NEA), VKM assesses whether genetically modified organisms (GMOs) intended for the European market can pose risks to human or animal health, or the environment in Norway. VKM assesses the scientific documentation regarding GMO applications seeking approval for use of GMOs as food and feed, processing, or cultivation. The EU Regulation 1829/2003/EC (Regulation) covers living GMOs that fall under the Norwegian Gene Technology Act, as well as processed food and feed from GMOs (dead material) that fall under the Norwegian Food Act. The regulation is currently not part of the EEA agreement or implemented in Norwegian law. Norway conducts its own assessments of GMO applications in preparation for the possible implementation of the Regulation. In accordance with the assignment by NFSA and NEA, VKM assesses GMO applications during scientific hearings initiated by the European Food Safety Authority (EFSA), as well as after EFSA has published its own risk assessment of a GMO, up until EU member countries vote for or against approval in the EU Commission. The assignment is divided into three stages. (link) Genetically modified maize DAS1131 DAS1131 is a genetically modified maize developed by Agrobacterium tumefaciens -mediated transformation. Maize DAS1131 plants contain the transgenes cry1Da2 and dgt-28 epsps which encode the protein Cry1Da2 and the enzyme DGT-28 EPSPS, respectively. Cry1Da2 provides resistance to certain susceptible Lepidopteran (order of butterflies and moths) pests and the enzyme DGT-28 EPSPS provides tolerance to glyphosate-based herbicides. VKM has assessed the documentation in application GMFF-2021-1530 and EFSA's scientific opinion on genetically modified maize DAS1131. VKM concludes that the applicant's scientific documentation for the genetically modified maize DAS1131 is satisfactory for risk assessment, and in accordance with EFSA guidelines for risk assessment of genetically modified plants for food or feed uses. The genetic modifications in maize DAS1131do not indicate an increased health or environmental risk in Norway compared with EU countries. EFSA's risk assessment is therefore sufficient also for Norwegian conditions. As no specific Norwegian conditions have been identified regarding properties of the genetically modified maize DAS1131, VKM's GMO panel has not performed a complete risk assessment of the maize. About the assignment: In stage 1, VKM shall assess the health and environmental risks of the genetically modified organism and derived products in connection with the EFSA scientific hearing of GMO applications. VKM shall review the scientific documentation that the applicant has submitted and possibly provide comments to EFSA. VKM must also consider: i) whether there are specific Norwegian conditions that could give other risks in Norway than those mentioned in the application, ii) whether the Norwegian diet presents a different health risk for the Norwegian population should the GMO be approved, compared to the European population, and iii) risks associated with co-existence with conventional and/or ecologic production of plants for GMOs seeking approval for cultivation. Relevant measures to ensure co-existence must also be considered. In stage 2, VKM shall assess whether comments from Norway have been satisfactorily answered by EFSA. In addition, VKM shall assess whether comments from other countries imply need for further follow-up. (...)Assessment of genetically modified maize DAS1131 for food and feed uses, import and processing under Regulation (EC) No 1829/2003 (application GMFF-2021-1530)publishedVersio
